menu
    • menu

    Company profile for Ark Biosciences

    NEW Drugs in Dev: 5
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a biopharmaceutical company focused on the discovery and development of therapeutics addressing unmet medical needs in respiratory and lung diseases. With a product portfolio covering full disease cycle and patient segmentations, our drug candidates address a spectrum of acute and chronic respiratory and lung diseases that currently lack effective treatments.Ark Biosciences is a biopharmaceutical company that is dedicat...
    We are a biopharmaceutical company focused on the discovery and development of therapeutics addressing unmet medical needs in respiratory and lung diseases. With a product portfolio covering full disease cycle and patient segmentations, our drug candidates address a spectrum of acute and chronic respiratory and lung diseases that currently lack effective treatments.Ark Biosciences is a biopharmaceutical company that is dedicated to the discovery and development

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ark BiosciencesChina Flag
    Country
    Country
    China
    Address
    Address
    Building 25, Lane 388, Shengrong Road, Pudong, Shanghai 201203
    Telephone
    Telephone
    +86 21 50681677
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.arkbiosciences.com/en
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Asia Pharma Expo

    Not Confirmed

    envelop Contact Supplier

    Asia Pharma Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ark Bio Gets China Approval For Aizhida In ADHD Treatment
    Ark Bio Gets China Approval For Aizhida In ADHD Treatment

    08 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ark-biopharmaceutical-receives-china-marketing-authorization-for-aizhida-for-the-treatment-of-adhd-302656307.html

    PR NEWSWIRE
    08 Jan 2026
    Share Share
    Arkbio Launches Phase II Trial Of AK0610, For Respiratory
    Arkbio Launches Phase II Trial Of AK0610, For Respiratory

    30 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/arkbio-initiates-phase-ii-clinical-trial-of-ak0610-a-preventive-monoclonal-antibody-for-respiratory-syncytial-virus-infection-302598172.html

    PR NEWSWIRE
    30 Oct 2025
    Share Share
    WHO Adds ArkBio's Ziresovir to Pediatric RSV Drug Priority List
    WHO Adds ArkBio's Ziresovir to Pediatric RSV Drug Priority List

    15 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/arkbios-ziresovir-included-into-pediatric-rsv-drug-priority-list-by-who-302505263.html

    PR NEWSWIRE
    15 Jul 2025
    Share Share
    ArkBio's ADHD drug Azstarys Granted Priority Review by China NMPA
    ArkBio's ADHD drug Azstarys Granted Priority Review by China NMPA

    15 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/arkbios-new-drug-application-for-adhd-therapeutic-azstarys-accepted-and-granted-priority-review-by-china-nmpa-302481819.html

    PR NEWSWIRE
    15 Jun 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search